Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRT2527 |
Synonyms | |
Therapy Description |
PRT2527 inhibits CDK9, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2022) 82 (12_Supplement): 5471). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRT2527 | PRT 2527|PRT-2527 | CDK9 Inhibitor 21 | PRT2527 inhibits CDK9, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2022) 82 (12_Supplement): 5471). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PBRM1 inact mut | clear cell renal cell carcinoma | predicted - sensitive | PRT2527 | Preclinical - Cell culture | Actionable | In a preclinical study, PRT2527 inhibited spheroid growth in clear cell renal cell carcinoma cell lines harboring inactivating PBRM1 mutations in culture (PMID: 38371625). | 38371625 |
PBRM1 loss | lung cancer | sensitive | PRT2527 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PRT2527 inhibited tumor growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). | 38371625 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05665530 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | POL | ITA | GBR | FRA | DEU | CHE | CAN | AUS | 1 |
NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Completed | USA | 0 |